Clinical Trial Update: A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical study of HuZAF, a humanized anti-Interferon-γ monoclonal antibody, for moderate-to-severe Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• HuZAF (humanized anti-Interferon-γ monoclonal antibody)

Snippet

Sponsor: Facet Biotech | Conditions: Crohn's Disease, Colitis | Phase 2 | Status: COMPLETED